Select your timezone:

Industry Symposium
Revolutionizing Transplant Care: Optimizing dd-cfDNA and Molecular Diagnostics

Monday September 12, 2022 | 13:10 to 14:10
Room: A
Track: N/A

Video is available - Log in to view. You must be registered to the event to view content

Organized by Natera


Description

Molecular insights help inform changes in practice that can impact patient care on a large scale. The Trifecta Study results will be presented by Dr. Philip Halloran from the Alberta Transplant Applied Genomics Centre (ATAGC) in Alberta, Canada. The Trifecta study analyzed a biopsy-matched kidney transplant cohort using both molecular microscopy and histology and showed the combination of dd-cfDNA fraction and estimated quantity was significantly more predictive for rejection than either variable alone. Next, Dr. Reza Motallebzadeh from the UCL Institute of Immunity & Transplantation in London will talk about the importance of an individualized IS regimen and using Prospera as a tool to achieve this goal. Later, Dr. Phil Gauthier, our lead Sr. Medical Director, will talk about innovations in kidney care using Renasight, a comprehensive genetic panel.

Presentations

Phil Halloran, Canada
Presenter

Phil Gauthier, United States
Presentation

Reza Motallebzadeh, United Kingdom

© 2022 TTS 2022